Table 1.
Patient's characteristics at baseline (n = 69 patients).
| Variables | n = 69 |
|---|---|
| Prior SLE medication history | |
| Prednisone use | 69 (100%) |
| Prednisone daily dose/mg, median (range) | 20 (5-500) |
| CYC use | 47 (68.1%) |
| MMF use | 19 (27.5%) |
| HCQ use | 31 (44.9%) |
| LEF use | 14 (20.3%) |
| Clinical and biological symptoms | |
| Fever | 25 (36.2%) |
| Rash | 44 (63.8%) |
| Photosensitivity | 33 (47.8%) |
| Oral ulcers | 12 (17.4%) |
| Arthralgia/arthritis | 49 (71.0%) |
| Serositis | 17 (24.6%) |
| Vasculitis | 14 (20.3%) |
| Alopecia | 19 (27.5%) |
| Renal disorder | 64 (92.8%) |
| Active lupus nephritis | 63 (91.3%) |
| Neurologic disorder | 5 (7.3%) |
| Cardiorespiratory disorder | 19 (27.5%) |
| Hematological disorder | 32 (46.4%) |
| Immunologic disorder | 40 (58.0%) |
| Antinuclear antibodies | 54 (78.3%) |
| Anti-dsDNA | 27 (39.1%) |
| Anti-Sm | 21 (30.4%) |
| Anti-SSA | 17 (24.6%) |
| Anti-SSB | 6 (8.7%) |
| Low complement | 30 (43.5%) |
| CYC induction | 42 (60.9%) |
| Allo-MSC transplantation | |
| Sources of MSCs (BM/UC) | 18/51 |
| Second MSCs | 24 (34.8%) |
| SLEDAI score at baseline, median (range) | 13 (8-34) |
| CR during 1 year | 16 (23.2%) |
| LDA during 1 year | 40 (58.0%) |
SLE: systemic lupus erythematosus; Anti-dsDNA: anti-double-stranded DNA antibody; Allo-MSCs: allogenic mesenchymal stem cells; BM: bone marrow-derived; UC: umbilical cord-derived; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; CYC: cyclophosphamide; MMF: mycophenolate mofetil; HCQ: hydroxychloroquine; LEF: leflunomide; CR: clinical remission; LDA: low disease activity.